Screener
NewAmsterdam Pharma Company NAMS Total debt
Total debt at other companies
Other financials
Where this comes from
Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $82K.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
FAQ
- What is NewAmsterdam Pharma Company's total debt?
- NewAmsterdam Pharma Company (NAMS) reported total debt of $82K in Q2 2026.
- How has NewAmsterdam Pharma Company's total debt changed year-over-year?
- NewAmsterdam Pharma Company's total debt decreased by 75.0% year-over-year, from $328K to $82K.
- What is the long-term trend for NewAmsterdam Pharma Company's total debt?
- Over 3 years (2022 to 2025), NewAmsterdam Pharma Company's total debt has grown at a 17.0% compound annual growth rate (CAGR), from $126K to $202K.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.
Ask your AI about NewAmsterdam Pharma Company's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude